1. A multilayer capacitor comprising:
a capacitor body having a multilayer structure including a plurality of stacked dielectric layers, and having a substantially rectangular parallelepiped shape including a first principal surface and a second principal surface extending substantially parallel to surfaces of the dielectric layers and opposed to each other, a first side surface and a second side surface opposed to each other, and a first end surface and a second end surface opposed to each other, the first and second end surfaces having a length greater than a length of the first and second side surfaces; and
a first external terminal electrode and a second external terminal electrode provided on the first end surface and on the second end surface of the capacitor body, respectively; wherein
the capacitor body includes a first capacitor portion and a second capacitor portion arranged adjacently in a direction in which the dielectric layers are stacked;
the first capacitor portion includes a first internal electrode and a second internal electrode opposed to each other with a dielectric layer therebetween to provide electrostatic capacity;
the second capacitor portion includes a third internal electrode and a fourth internal electrode opposed to each other with a dielectric layer therebetween to provide electrostatic capacity;
the first internal electrode includes a first capacity portion and a first lead portion which is led out from the first capacity portion to extend to the first end surface and which is electrically connected to the first external electrode;
the second internal electrode includes a second capacity portion opposed to the first capacity portion via a dielectric layer, and a second lead portion which is led out from the second capacity portion to extend to the second end surface and which is electrically connected to the second external electrode;
the third internal electrode includes a third capacity portion and a third lead portion which is led out from the third capacity portion to extend to the first end surface and which is electrically connected to the first external electrode;
the fourth internal electrode includes a fourth capacity portion opposed to the third capacity portion via a dielectric layer, and a fourth lead portion which is led out from the fourth capacity portion to extend to the second end surface and which is electrically connected to the second external electrode; and
the third lead portion includes a region that is narrower than the first lead portion.
2. The multilayer capacitor according to claim 1, wherein the fourth lead portion includes a region that is narrower than the second lead portion.
3. The multilayer capacitor according to claim 1, wherein, in the second capacitor portion, a plurality of third internal electrodes are arranged continuously in a stacking direction of the dielectric layers.
4. The multilayer capacitor according to claim 1, wherein the second capacitor portion is sandwiched between two first capacitor portions in the capacitor body, and the capacitor body is arranged to be mounted on a mounting surface such that one of the first and second principal surfaces is arranged to face the mounting surface.
5. A multilayer capacitor comprising:
a capacitor body having a multilayer structure including a plurality of stacked dielectric layers, and having a substantially rectangular parallelepiped shape including a first principal surface and a second principal surface opposed to each other, a first side surface and a second side surface extending substantially parallel to surfaces of the dielectric layers and opposed to each other, and a first end surface and a second end surface opposed to each other; and
a first external terminal electrode and a second external terminal electrode provided on at least the second principal surface of the capacitor body and arranged to be isolated from each other; wherein
the capacitor body includes a first capacitor portion and a second capacitor portion arranged adjacently in a direction in which the dielectric layers are stacked;
the first capacitor portion includes a first internal electrode and a second internal electrode opposed to each other with a dielectric layer therebetween to provided electrostatic capacity;
the second capacitor portion includes a third internal electrode and a fourth internal electrode opposed to each other with a dielectric layer therebetween to provide electrostatic capacity;
the first internal electrode includes a first capacity portion and a first lead portion which is led out from the first capacity portion to extend to the second principal surface and which is electrically connected to the first external electrode;
the second internal electrode include a second capacity portion opposed to the first capacity portion via a dielectric layer, and a second lead portion which is led out from the second capacity portion to extend to the second principal surface and which is electrically connected to the second external electrode;
the third internal electrode includes a third capacity portion and a third lead portion which is led out from the third and is electrically connected to the first external electrode;
the fourth internal electrode includes a fourth capacity portion opposed to the third capacity portion via a dielectric layer, and a fourth lead portion which is led out from the fourth capacity portion and is electrically connected to the second external electrode;
the third lead portion includes a region that is narrower than the first lead portion when the third lead portion and the first lead portion are compared in the same direction; and
the multilayer capacitor arranged to be mounted on a mounting surface with the second principal surface arranged to face a mounting surface.
6. The multilayer capacitor according to claim 5, wherein the third lead portion and the fourth lead portion extend to the second principal surface.
7. The multilayer capacitor according to claim 5, wherein the first external terminal electrode is arranged to extend from the second principal surface to at least the first end surface, the third lead portion is arranged to extend to the first end surface for electrical connection with the first external terminal electrode, the second external terminal electrode is arranged to extend from the second principal surface to at least the second end surface, and the fourth lead portion is arranged to extend to the second end surface for electrical connection with the second external terminal electrode.
8. The multilayer capacitor according to claim 5, wherein the first external terminal electrode is arranged to extend from the second principal surface to the first principal surface through the first end surface and through the first and second side surfaces, and the second external terminal electrode is arranged to extend from the second principal surface to the first principal surface through the second end surface and through the first and second side surfaces.
9. The multilayer capacitor according to claim 5, wherein the fourth lead portion includes a region that is narrower than the second lead portion when the fourth lead portion and the second lead portion are compared in the same direction.
10. The multilayer capacitor according to claim 5, wherein, in the second capacitor portion, a plurality of third internal electrodes are arranged continuously in a stacking direction of the dielectric layers.
11. The multilayer capacitor according to claim 5, wherein the second capacitor portion is sandwiched between two first capacitor portions in the capacitor body.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
What is claimed is:
1. An antisense oligonucleotide or analog thereof comprising 10 or more contiguous bases or base analogs from the sequence of bases of sequence A, B, C, D, E, F, G, H, I, J, K, L, or M of FIG. 1.
2. An antisense oligonucleotide or analog thereof comprising a sequence having 90% of greater identity to sequence A, B, C, D, E, F, G, H, I, J, K, L, or M of FIG. 1.
3. An antisense oligonucleotide or analog thereof comprising nucleotide sequence A, B, C, D, E, F, G, H, I, J, K, L, or M of FIG. 1.
4. The antisense oligonucleotide of claim 3, wherein the nucleotide sequence comprises nucleotide sequence A, A, B, C, C, D, E, E, F, G, G, H, H, I, I, J, K, K, L, L, M, or M of FIGS. 2A and 2B.
5. The antisense oligonucleotide of claim 3, wherein the oligonucleotide is conjugated to a peptide.
6. The antisense oligonucleotide of claim 3, wherein the oligonucleotide is encapsulated in a liposome or nanoparticle.
7. The antisense oligonucleotide of claim 3, wherein the phosphate backbone comprises phosphorothioate bonds.
8. The antisense oligonucleotide of claim 3, wherein the backbone is bonded to one or more lipid substituents.
9. The antisense oligonucleotide of claim 3, wherein one or more of the oligonucleotide’s sugars contain an -OMe group at their 2 position.
10. The antisense oligonucleotide of claim 3, wherein the phosphate backbone consists essentially of phosphorothioate bonds.
11. The antisense oligonucleotide of claim 7, wherein the phosphorothioate is stereo regular.
12. The antisense oligonucleotide of claim 3, wherein the oligonucleotide is linked to an intercalating agent, a cross-linker, an endonuclease, a lipophilic carrier, an alkylating agent, a coordination complex, or a peptide conjugate, or a combination thereeof
13. The antisense oligonucleotide of claim 3, wherein the oligonucleotide is modified to reduce its ionic charge or increase its hydrophobicity.
14. The antisense oligonucleotide of claim 13, wherein the oligonucleotide comprises one or more short chain alkyl structures that replace some of the oligonucleotide’s phosphodiester bonds.
15. The antisense oligonucleotide of claim 13, wherein the oligonucleotide is linked to one or more cholesteryl moieties.
16. The antisense oligonucleotide of claim 3, wherein the oligonucleotide comprises one or more bases with a C-5 propynyl pyrimidine modification.
17. A method of treating cancer, comprising introducing into a tumor cell an effective amount of the antisense oligonucleotide of claim 16, thereby reducing the levels of bcl-2 protein produced and treating cancer.
18. The method of claim 17, wherein the cancer is epithelial cancer.
19. The method of claim 18, wherein the epithelial cancer is prostate cancer.
20. The method of claim 18, wherein the epithelial cancer is lung cancer.
21. The method of claim 18, wherein the epithelial cancer is bladder cancer.
22. The method of claim 17, wherein the introducing comprises using a lipid as a delivery agent.
23. The method of claim 17, wherein the introducing comprises using porphyrin or lipofectin as a delivery agent.
24. The method of claim 17, wherein the effective amount is between 0.1 M and 10 M.
25. The method of claim 17, wherein the effective amount is between 0.1 M and 4 M.
26. The method of claim 17, wherein the effective amount is between 0.4 M and 1 M.
27. A method of treating cancer, comprising introducing into a tumor cell an effective amount of the antisense oligonucleotide of claim 3, thereby reducing the levels of bcl-xL protein produced and treating cancer.
28. The method of claim 27, wherein the cancer is epithelial cancer.
29. The method of claim 28, wherein the epithelial cancer is prostate cancer.
30. The method of claim 28, wherein the epithelial cancer is lung cancer.
31. The method of claim 28, wherein the epithelial cancer is bladder cancer.
32. The method of claim 27, wherein the introducing comprises using a lipid as a delivery agent.
33. The method of claim 27, wherein the introducing comprises using porphyrin or lipofectin as a delivery agent.
34. The method of claim 27, wherein the effective amount is between 0.1 M and 10 M.
35. The method of claim 27, wherein the effective amount is between 0.1 M and 4 M.
36. The method of claim 27, wherein the effective amount is between 0.4 M and 1 M.
37. A method of promoting the regression of vascular lesions, comprising introducing into a vascular cell an amount of the antisense oligonucleotide of claim 3 effective to reduce the levels of bcl-xL protein produced, thereby promoting the regression of vascular lesions.
38. The method of claim 37, wherein the introducing comprises using a lipid as a delivery agent.
39. The method of claim 37, wherein the introducing comprises using porphyrin or lipofectin as a delivery agent.
40. The method of claim 37, wherein the effective amount is between 0.1 M and 4 M.
41. The method of claim 37, wherein the effective amount is between 0.4 M and 1 M.
42. A pharmaceutical composition comprising an effective amount of the antisense oligonucleotide or analog thereof of claim 3 and a pharmaceutically acceptable carrier.
43. The pharmaceutical composition of claim 42, wherein the effective amount is between 0.1 M and 10 M.
44. The pharmaceutical composition of claim 42, wherein the effective amount is between 0.1 M and 4 M.
45. The pharmaceutical composition of claim 42, wherein the effective amount is between 0.4 M and 1 M.
46. The pharmaceutical composition of claim 42, wherein the oligonucleotide is encapsulated in a liposome or nanoparticle.
47. The pharmaceutical composition of claim 42, wherein the pharmaceutical composition comprises tetra meso-(4-methylpyridyl)porphine or tetra meso-(anilinium)porphine or a combination thereof.